目的 探討武漢市第三醫(yī)院新型冠狀病毒肺炎（COVID-19）患者治療期間發(fā)生藥物性肝功能異常的一般規(guī)律和特點，為臨床安全用藥提供參考。方法 收集2020年1月27日-2020年3月8日武漢市第三醫(yī)院出現(xiàn)的藥物致肝功能異常的COVID-19患者資料，對患者用藥、肝功能檢查值、治療和轉(zhuǎn)歸情況進(jìn)行回顧性分析。結(jié)果 COVID-19患者治療過程中出現(xiàn)藥源性肝功能異常的男性較多（P<0.01），且51~70歲是高發(fā)階段；60%以上的患者應(yīng)用治療COVID-19各類藥物均達(dá)到2種及以上，對癥治療藥物合并用藥3種及以上藥物達(dá)到51.96%。結(jié)論 COVID-19診療過程中，警惕中老年男性患者聯(lián)合用藥造成的藥物性肝功能異常，減輕肝臟負(fù)擔(dān)，加強(qiáng)用藥監(jiān)護(hù)并及時對癥處理。

Objective To investigate the general rules and characteristics of drug-induced liver dysfunction during the treatment of COVID-19, and to provide references for safe clinical use. Methods Data of COVID-19patients with drug-induced abnormal liver function during treatment in The Third Hospital of Wuhan from January 27, 2020 to March 3, 2020 were collected. Results During the treatment of COVID-19, drug-induced liver dysfunction was more common in males (P<0.05), and the incidence was high between 51 and 70 years old, more than 60% of the patients received two or more drugs for treatment COVID-19, and the combination of three or more symptomatic drugs reached 51.96%. Conclusion During the diagnosis and treatment of COVID-19, doctors should be on guard against the drug-induced liver dysfunction caused by the combination of drugs in middle-aged and elderly male patients, to reduce the burden on the liver, and strengthen medication monitoring and timely supply symptomatic treatment.

R974

國家自然科學(xué)基金資助項目（81603352）